Endo International plc (ENDP), Newell Brands Inc. (NWL)

Postado Novembro 15, 2017

Canaccord Genuity analyst Dewey Steadman reiterated a Hold rating on Endo International (NASDAQ: ENDP) on November 12 and set a price target of $8. The brokerage presently has a "neutral" rating on the stock. Analysts set a 12-month price target of $122.28 a share. Also, the current price highlights a discount of 24.78% to analysts' high consensus price target. Comparatively, Endo International plc posted earnings of $1.09 per share in the same quarter previous year. Mizuho reaffirmed a buy rating on shares of Endo International PLC in a research report on Friday. Zacks Investment Research raised shares of Endo International PLC from a "hold" rating to a "buy" rating and set a $9.75 price objective on the stock in a research note on Wednesday, October 11th. Teachers Retirement System of The State of Kentucky now owns 36,400 shares of the company's stock worth $406,000 after buying an additional 8,400 shares during the last quarter. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.

Moving average convergence divergence (MACD) shows that the stock is on a PRICE RELATIVITY trend.

Endo International PLC (NASDAQ:ENDP) last released its quarterly earnings data on Monday, August 8th.

Endo International PLC has a 52 week low of $7.40 and a 52 week high of $21.87 Endo International PLC's market capitalization is now $0. The company has a 50-day moving average of $20.33 and a 200-day moving average of $19.67.

Endo International plc (ENDP) has the market capitalization of $1.49 Billion. The company reported $0.91 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.85 by $0.06.

For the Current Quarter, the growth estimate for Endo International plc is -65%, while for the Next Quarter the stock growth estimate is -43.9%. The company had revenue of $786.90 million for the quarter, compared to the consensus estimate of $794.93 million. During the same quarter a year ago, the business posted $1.01 EPS. Now shares of Endo Int'l Plc (NASDAQ:ENDP) have an average brokerage recommendation (ABR) of 2.57 number of Recs in ABR is 14 however the company's industry rank by ABR is out of 265. Royal Bank Of Canada reissued a sector perform rating and issued a $9.00 price target (down previously from $15.00) on shares of Endo International PLC in a research note on Wednesday, August 9th. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of USA and worldwide trademark & copyright law. The correct version of this report can be read at https://www.dispatchtribunal.com/2017/11/13/endo-international-plc-endp-pt-lowered-to-7-00.html. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Large investors have recently bought and sold shares of the company. Van ECK Associates Corp raised its position in Endo International PLC by 54.1% in the second quarter. Alps Advisors Inc. now owns 250,511 shares of the company's stock valued at $2,146,000 after purchasing an additional 21,373 shares during the last quarter. TIAA CREF Investment Management LLC boosted its holdings in shares of Endo International PLC by 1.6% during the second quarter. Van ECK Associates Corp now owns 117,695 shares of the company's stock valued at $1,835,000 after buying an additional 41,331 shares during the period. Capstone Asset Management Co. increased its holdings in shares of Endo International PLC by 3.1% during the 2nd quarter. Institutional investors and hedge funds own 90.50% of the company's stock. Its International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas, including attention deficit hyperactivity disorder, pain, womenÂ's health, and oncology; generic, branded generic, and over-the-counter products in the areas of dermatology and anti-infectives; and healthcare services, products, and solutions to hospitals, pharmacies, and practitioners, as well as for government healthcare programs. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.